← All Signals

🏥 FDA: Rising Pharma Holding, Inc. — Class II

healthcarebearishSource: FDA
80%Confidence
0Views
FDASource
2026-03-26Date

Summary

Temozolomide Capsules recall due to stability testing failures indicates potential degradation issues that could compromise cancer treatment efficacy. This may create temporary shortages and increase scrutiny on Rising Pharma's manufacturing processes.

Actionable: Check Temozolomide inventory and consider alternative suppliers until stability issues are resolved.

AI Confidence: 80%

Data Points

firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now